================================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
-------------------
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
-----------
Date of Report (Date of Earliest Event Reported): September 19, 1996
U.S. BIOSCIENCE, INC.
- --------------------------------------------------------------------------------
(Exact Name of Registrant as Specified in its Charter)
Delaware
- --------------------------------------------------------------------------------
(State or Other Jurisdiction of Incorporation)
1-10392 23-2460100
- ------------------------------ -------------------------------------
(Commission File Number) (I.R.S. Employer Identification No.)
One Tower Bridge
100 Front Street
West Conshohocken, Pennsylvania 19428
- ---------------------------------------- ------------------------------
(Address of Principal Executive Offices) (Zip Code)
(610) 832-0570
- --------------------------------------------------------------------------------
(Registrant's Telephone Number, Including Area Code)
N/A
- --------------------------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
================================================================================
Item 5. Other Events
------------
Amendment of Distribution and Supply Agreement
-----------------------------------------------
On September 24, 1996, the Company announced an agreement with an
affiliate of Schering-Plough Corporation to amend their 1993 European
distribution agreement (the "Agreement") for Ethyol(R) (amifostine), U.S.
Bioscience's cytoprotective product. The Agreement is filed as Exhibit 10.16 to
the Company's Annual Report on Form 10-K and incorporated herein by reference.
The amendment reported herein (the "Amendment") is attached hereto as Exhibit
10.16.1 and incorporated herein by reference. The following description is
qualified by reference to such exhibits.
Under terms of the amended Agreement, effective January 1, 1996,
Schering-Plough will purchase Ethyol from U.S. Bioscience at a price based on a
percent of net sales and U.S. Bioscience will no longer absorb certain
promotional expenses previously shared by the parties. In addition, Schering-
Plough's exclusive marketing period will be extended by two years, through 2003,
and Schering-Plough will provide U.S. Bioscience with a net incremental payment
of $3.4 million. Following that exclusive period, U.S. Bioscience may elect to
enter into a two-year transition period in which U.S. Bioscience would co-
promote Ethyol in Europe and thereafter all rights to market Ethyol in Europe
will revert to U.S. Bioscience.
2
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits
- ------- ------------------------------------------------------------------
(c) Exhibits.
*10.16.1 Amendment to Distribution and Supply Agreement, dated as of
August 31, 1996, between the Company and Scherico, Ltd.
-------------
* Confidential Treatment Requested
3
SIGNATURES
----------
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
U.S. BIOSCIENCE, INC.
By: /s/ Robert I. Kriebel
---------------------------------
Name: Robert I. Kriebel
Title: Senior Vice President
September 24, 1996
4
EXHIBIT INDEX
Exhibit No. Description Page
- ----------- ----------- ----
*10.16.1 Amendment to Distribution and Supply Agreement,
dated as of August 31, 1996, between the Company and
Scherico, Ltd.
____________
* Confidential Treatment Requested
5